Other grades of this product :
| Quinapril Basic information |
| Product Name: | Quinapril | | Synonyms: | QUINAPRIL HCL;PD-109452-2;CI-906;(3S)-2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-Isoquinolinecarboxylic acid;(S)-2-((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)aMino)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;ACCUPRIL;ACCUPRIN;ACCUPRO | | CAS: | 85441-61-8 | | MF: | C25H30N2O5 | | MW: | 438.52 | | EINECS: | 1312995-182-4 | | Product Categories: | | Mol File: | 85441-61-8.mol |
| Quinapril Chemical Properties |
| Melting point | 120-130°C | | Boiling point | 662.0±55.0 °C(Predicted) | | density | 1.217±0.06 g/cm3(Predicted) | | pka | 3.39±0.20(Predicted) | | CAS DataBase Reference | 85441-61-8(CAS DataBase Reference) |
| Quinapril Usage And Synthesis |
| Description | Quinapril is an orally active, non-sulfhydryl ACE inhibitor reportedly useful in the
treatment of essential hypertension. The main claimed advantage of quinapril compared
with other available ACE inhibitors is its side-effect profile. It is also effective in the management of congestive heart failure. | | Originator | Warner-Lambert (USA) | | Uses | Antihypertensive; enzyme inhibitor (angiotensin-converting). | | Brand name | Accupril (Pfizer); Quinapril (Lupin); Quinapril (Ranbaxy)
;Accupro. | | Clinical Use | Angiotensin converting enzyme inhibitor:
Hypertension
Congestive heart failure | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARBs and
aliskiren.
Bee venom extract: possible severe anaphylactoid
reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and
nephrotoxicity.
Cytotoxics: increased risk of angioedema with
everolimus.
Diuretics: enhanced hypotensive effect;
hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.
Gold: flushing and hypotension with sodium
aurothiomalate.
Lithium: reduced excretion (possibility of enhanced
lithium toxicity).
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and
nephrotoxicity. | | Metabolism | Quniapril is a prodrug which is metabolised in the liver
to its active form, quinaprilat, and to minor inactive
metabolites.
Quinaprilat is eliminated primarily by renal excretion. |
| Quinapril Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye